Canadian speciality pharmaceutical company Paladin Labs has completed the acquisition of all outstanding common shares of Labopharm.

Labopharm develops novel polymeric, nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs.

Paladin Labs interim president and CEO Mark Beaudet said that, through the addition of established international revenue streams, the acquisition will provide them the opportunity to build upon their existing operational capabilities.